We are live on ! Find out more

Serina Therapeutics

SER

Market cap $56.4M

2.22 USD

-0.28

11.2%

At close Updated Sep 11, 4:00 PM EDT

1 day

-11.2%

5 days

-17.78%

1 month

-20.14%

3 months

22.65%

6 months

48%

Year to date

6.73%

1 year

-56.47%

5 years

-93.64%

10 years

-97.67%

About: Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Employees: 16

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend one-on-one investor meetings during the conference taking place September 14-16, 2026 in New York, New York.

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2

- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027 - HUNTSVILLE, Ala., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson's disease and recommended that the study advance to Cohort 2.

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates.

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board's Audit and Compensation Committees.

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem , a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology.

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads – HUNTSVILLE, AL, April 07, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Serina Therapeutics Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 5th LNP Formulation & Process Development Summit in Boston, MA. Entitled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform", Dr. Moreadith will present data demonstrating the POZ-lipid in Serina's platform failed to elicit an antibody response to the polymer in a vaccine format in the rat.

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

See News Rankings

Price charts implemented using Lightweight Charts™